AB0313 CLINICAL FEATURE OF 100 CASES OF METHOTREXATE ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS WITH RA PATIENT

Background Lymphoproliferative disorders (LPDs), including malignant lymphoma, are known to occur in RA patients treated with disease modified antirheumatic drugs (DMARDs). In particular, LPD associated methotrexate (MTX)-treated is often referred as MTX-associated (MTX-LPD). MTX-LPD have various clinical feature and histological findings 1) . We accumulated cases rheumatoid arthritis (MTX-RA-LPD). Objectives clarified the characteristics of MTX-RA-LPD. addition, we examine prognosis patients. Methods enrolled 100 who diagnosed from 2005 2021. collected follow data based on reports retrospectively; age, 2) gender, 3) duration onset onset, 4) total dose MTX, 5) MTX administration, 6) presence extranodal lesion 7) findings, 8) treatment for LPD, 9) 5-year survival rate. Results The mean age MTX-RA-LPD (M:F=30:70) were 66.7 ± 10.7 years old, 25.2 11.0 years. administration over 2,600mg 5 years, respectively. lesions found 51%, diffuse large B cell lymphoma was most common findings. Spontaneous regression observed 68%. rate high 85%. Conclusion features similar those previous reports. Furthermore, suggested a good References [1]Harigai M. era widespread use methotrexate: A review literature current perspective. Mod Rheumatol. 2018 Jan;28(1):1-8. Disclosure Interests None declared